Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib The Children’s Oncology Group AAML0631 ...

Please provide your email address to receive an email when new articles are posted on . Children with acute promyelocytic leukemia achieved excellent survival rates with low risk for relapse following ...

Children with acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA) plus arsenic trioxide -- without maintenance therapy -- were able to achieve outcomes similar to the ...

All-trans retinoic acid and arsenic trioxide used together can let children avoid treatment with convention chemotherapy, which has more adverse effects. ATRA/arsenic trioxide therapy is the preferred ...

Please provide your email address to receive an email when new articles are posted on . Children with acute promyelocytic leukemia achieved survival benefit with an all-trans retinoic acid and arsenic ...

Data published online today in Blood, the Journal of the American Society of Hematology (ASH) describe the work of an ASH international clinical network collaborative focused on modernizing treatment ...

A clinical trial has found that the combination of all-trans retinoic acid, which is a metabolite of vitamin A, and arsenic trioxide is highly effective in children with standard- and high-risk acute ...

"Remarkable" results with a novel treatment regimen in pediatric acute promyelocytic leukemia (APL) have been reported by researchers at the National Cancer Institute (NCI). Two-year event free ...

A previous (LPA99) trial had demonstrated a high antileukemic efficacy of a risk-adapted strategy of all-trans retinoic acid (ATRA) and anthracycline chemotherapy as induction and consolidation ...